Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by WarrantOfficeron Apr 05, 2021 10:44am
126 Views
Post# 32936890

Strategic Planning

Strategic Planning It may seem at times I am a little critical of there NR. Their NR always leave me asking more questions. Voyageur has had a couple of years to anaylse markets and predetermine a prioritized international markets list as soon as Health Canada approval was granted. According to their statement below, they are not anywhere near this level of readiness. Perhaps, the hiring of highly experienced radiographic contrast media professionals will assist Voyageur in their stratgic planning. BTW, thumbs up to a third approval. 

Approval timelines and high profit margin are the criteria for Voyageur’s international sales strategy. Voyageur is actively analyzing international markets, where recognition of Voyageur's Health Canada registrations is anticipated to assist Voyageur in obtaining licenses in an expeditious manner. Upon conclusion of our analysis, Voyageur will begin applying for registration applications on a country-by-country basis, including FDA licenses in the USA
<< Previous
Bullboard Posts
Next >>